Big Money Are Crazy For Capricor Therapeutics Inc (NASDAQ:CAPR), Sentiment at 4.33

May 16, 2018 - By Sharla Beadle

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Corporate Logo

Capricor Therapeutics Inc’s Sentiment

In Q4 2017 Capricor Therapeutics Inc (NASDAQ:CAPR) big money sentiment increased to 4.33, according to SEC.gov filings. So its up 2.53, from 2017Q3’s 1.8. 13 hedge funds increased and started new equity positions, while 3 sold and reduced their holdings in Capricor Therapeutics Inc so the sentiment is more positive. Funds own 4.44 million shares, up from 735,965 shares in 2017Q3. Funds holding Capricor Therapeutics Inc in top 10 changed to 0 from 0 for the same number . In total 3 funds closed positions, 0 reduced and 6 increased. Also 7 funds bought new Capricor Therapeutics Inc stakes.

Largest Capricor Therapeutics Inc Investors

Apriem Advisors owns 50,000 shares in Capricor Therapeutics Inc as of Q4 2017. As of Q4 2017, 1.14 million shares of Capricor Therapeutics Inc are owned by Brown Advisory Inc. In addition, Cordasco Financial Network reported 3,100 shares in Capricor Therapeutics Inc equivalent to 0.01% of its stocks portfolio. Granite Point Capital Management L.P. revealed 33,750 shares position in Capricor Therapeutics Inc. The Massachusetts-based fund Acadian Asset Management Llc looks positive on Capricor Therapeutics Inc, possessing 47,489 shares.

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases.The firm is worth $37.72 million. The companyÂ’s development stage drug candidates for cardiovascular diseases include CAP-1002 that is in Phase II clinical trials; and CAP-2003, which is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions.14.56 is the P/E ratio.

CAPR touched $1.31 during the last trading session after $0.01 change.Capricor Therapeutics, Inc. has volume of 121,337 shares. Since May 16, 2017 CAPR has declined 60.12% and is downtrending. The stock underperformed the S&P500 by 71.67%.

On August, 9 WallStreet anticipated Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s earnings report, RTT reports. Analysts predict $-0.11 earnings per share, which is $0.05 up or 31.25 % from 2017’s $-0.16 earnings per share. After $-0.14 EPS report previous quarter, Wall Street now predicts -21.43 % EPS growth of Capricor Therapeutics, Inc..

Royal Retail Bank Of Canada invested in 0% or 232 shs. Acadian Asset Mgmt Lc invested in 47,489 shs. Vanguard Inc owns 0% invested in Capricor Therapeutics, Inc. (NASDAQ:CAPR) for 713,756 shs. Brown Advisory invested 0.01% of its capital in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Germany-based Deutsche National Bank & Trust Ag has invested 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Northern Trust has invested 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Cordasco Financial holds 0.01% or 3,100 shs. Wells Fargo And Com Mn has 35,300 shs for 0% of their capital. Fincl Architects has 0% invested in Capricor Therapeutics, Inc. (NASDAQ:CAPR) for 2,000 shs. Granite Point Mngmt L P accumulated 33,750 shs. Apriem has 50,000 shs. Blackrock has invested 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). 6,500 are owned by Bankshares Of America De. Geode Cap Mgmt Limited accumulated 76,996 shs. Fincl Bank Of Ny Mellon owns 27,442 shs.

For more Capricor Therapeutics, Inc. (NASDAQ:CAPR) news announced briefly go to: Benzinga.com, Nasdaq.com, Nasdaq.com, Globenewswire.com or Nasdaq.com. The titles are as follows: “Benzinga’s Top Upgrades, Downgrades For May 16, 2018” announced on May 16, 2018, “Capricor Announces Initiation of HOPE-2 Clinical Trial of CAP-1002 for Duchenne Muscular Dystrophy” on April 30, 2018, “Capricor Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update” with a publish date: May 10, 2018, “Capricor Therapeutics to Present First Quarter 2018 Financial Results and Corporate Update on May 10” and the last “Capricor to Present on Exosomes at the Plenary Session of the International Society for Cellular Therapy in Montreal” with publication date: May 03, 2018.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: